RedHill Biopharma: Rises on manufacturing deal for COVID-19 treatment

Cosmo NV

28/01/2021 14:53

** Israeli drugmaker's U.S.-listed shares  RDHL.O  rise 1.2%
to $8.81
    ** Co enters agreement with Cosmo Pharmaceuticals NV
 COPN.S  to boost manufacturing capacity for RDHL's COVID-19
drug candidate, opaganib  urn:newsml:reuters.com:*:nPn5TcTjta
    ** RDHL says move is in preparation for prospective demand
following potential global emergency use authorizations for drug
    ** Says global mid-to-late stage study of opaganib underway
and interim analysis by an independent safety monitoring panel
will be conducted in coming days 
    **  Co in Nov reported collaborations with two U.S.-based
manufacturers to ramp up manufacturing of opaganib  urn:newsml:reuters.com:*:nL4N2IB3C5
    ** Stock up 7.7% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))